Biomark Capital

Eden Biologics is a biopharmaceutical company founded in 2012 and headquartered in Zhubei City, Taiwan. The company specializes in contract development and manufacturing services aimed at accelerating the development programs of its partners in the biopharmaceutical sector. It offers a comprehensive range of services, including cell line development, process development, analytical services, formulation development, and cGMP manufacturing. Eden Biologics is committed to making high-quality biologic medicines affordable and accessible by leveraging advanced process and engineering technologies that simplify and reduce the costs associated with mammalian cell culture manufacturing. The company operates state-of-the-art manufacturing facilities in Asia, adhering to US, EU, and ICH cGMP regulations, and is led by a team of experienced professionals with backgrounds in leading biopharmaceutical companies.

Eden Biologics is a biopharmaceutical company founded in 2012 and headquartered in Zhubei City, Taiwan. The company specializes in contract development and manufacturing services aimed at accelerating the development programs of its partners in the biopharmaceutical sector. It offers a comprehensive range of services, including cell line development, process development, analytical services, formulation development, and cGMP manufacturing. Eden Biologics is committed to making high-quality biologic medicines affordable and accessible by leveraging advanced process and engineering technologies that simplify and reduce the costs associated with mammalian cell culture manufacturing. The company operates state-of-the-art manufacturing facilities in Asia, adhering to US, EU, and ICH cGMP regulations, and is led by a team of experienced professionals with backgrounds in leading biopharmaceutical companies.

BetterDoctor, Inc. is a company based in San Francisco, California, that specializes in developing web and mobile applications to assist users in finding healthcare providers. Founded in 2011, BetterDoctor allows users to specify the type of doctor they need and select their insurance plan to view a list of verified healthcare professionals. The company's platform provides accurate provider data to health plans, health systems, and various organizations through its API, facilitating the search for doctors and improving healthcare access. BetterDoctor's services have reached millions of users, powering numerous health plans and companies by enhancing the transparency and reliability of doctor data. As of June 2018, BetterDoctor operates as a subsidiary of Quest Analytics, L.L.C.

Eden Biologics is a biopharmaceutical company founded in 2012 and headquartered in Zhubei City, Taiwan. The company specializes in contract development and manufacturing services aimed at accelerating the development programs of its partners in the biopharmaceutical sector. It offers a comprehensive range of services, including cell line development, process development, analytical services, formulation development, and cGMP manufacturing. Eden Biologics is committed to making high-quality biologic medicines affordable and accessible by leveraging advanced process and engineering technologies that simplify and reduce the costs associated with mammalian cell culture manufacturing. The company operates state-of-the-art manufacturing facilities in Asia, adhering to US, EU, and ICH cGMP regulations, and is led by a team of experienced professionals with backgrounds in leading biopharmaceutical companies.

i2Dx is developing a multimodal, cloud-based diagnostic platform for the assessment of neurological disorders. The platform will provide quantitative digital assessments of a number of biomarkers that are indicative of brain health with the goal of providing a personalized, longitudinal brain record for healthy individuals and patients.

WhiteGlove Health, Inc. is a mobile healthcare provider based in Austin, Texas, specializing in delivering primary care, preventive medical services, and support for individuals with chronic conditions directly in their homes and workplaces. Founded in 2006, the company has expanded its services across major cities including Dallas/Fort Worth, Houston, San Antonio, and Phoenix. WhiteGlove Health focuses on enhancing healthcare experiences while reducing costs for health plans by minimizing unnecessary medical utilization and insurance claims. Their clinical team, composed of board-certified nurse practitioners and registered nurses, collaborates with physicians and healthcare providers to offer comprehensive care. The company introduced its Value-Based Care division in 2014, targeting high-risk patients and facilitating at-home care to avoid hospital admissions and emergency visits. Through proactive monitoring and intervention, WhiteGlove Health aims to improve patient outcomes and streamline healthcare delivery. In 2014, the company acquired Glenridge Healthcare Solutions, enhancing its capabilities with advanced analytics and technology to better serve its clients.

WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.

Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hot diseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland.

Flexible Stenting Solutions, Inc. is a privately held medical device company focused on the development and commercialization of flexible stents built on a proprietary design platform. The company has developed a third generation self-expanding stent designed for the harsh loading conditions present in the superficial femoral and popliteal arteries. Their fully connected stent has coupled technology with clinical needs by providing a highly durable and fatigue resistant stent with superior radial stiffness and low chronic outward force. The key to the stent technology is the integration of helically wound struts with helical flexible coils providing a mechanism optimized for vigorous applications. The key to the delivery technology is simplicity, ease of use and placement. Flexible Stenting Solutions received CE Mark authorization for both its FlexStent® Femoropopliteal and Biliary Self Expanding (SE) Stent Systems in January 2009. The company received 510(k) clearance for its FlexStent® Biliary Self Expanding Stent System in September 2009. This stent will provide a significant benefit to patients requiring palliation of malignant biliary strictures by relieving symptoms caused by biliary obstruction.

HyperMed Imaging, Inc. is focused on developing advanced hyperspectral imaging technologies for medical applications, particularly in the area of surface tissue oximetry. Founded in 2006 and headquartered in Memphis, Tennessee, the company has created the HyperView Imaging System, which utilizes a proprietary spectrometer to provide a two-dimensional map of tissue oxygenation. Its flagship product, OxyVu, has received FDA 510(k) approval and is designed for use in clinical diagnostics, helping healthcare professionals assess microvasculature perfusion and improve patient care. Published studies have highlighted OxyVu's effectiveness in evaluating wound healing, diabetic foot ulcers, and planning for amputations. HyperMed's innovations address a significant market opportunity in clinical diagnostics, with the potential to impact the care of patients suffering from vascular diseases and diabetes.

MabVax Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative anti-cancer immunotherapies. The company utilizes two primary technology platforms: a series of cancer vaccines developed at Memorial Sloan-Kettering Cancer Center, which are currently in Phase II clinical trials for soft tissue sarcoma and ovarian cancer, and a human antibody discovery platform that leverages immune responses from patients successfully immunized with these vaccines. MabVax’s lead human antibody candidate is in preclinical evaluation for potential treatments targeting colon, pancreatic, and breast cancers. The company has secured significant federal grant funding to support its research and development efforts, underscoring its commitment to advancing novel therapeutic options for cancer patients.